Next-Generation GLP-1 Therapy: An Introduction to Liraglutide

References

• . Levy P. The current unmet need in type 2 diabetes mellitus: Addressing glycemia and cardiovascular disease. Postgrad Med. 2009; 121(3 suppl 1):S7–S12
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Buse JB, Davidson MB, . Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Rodbard H, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: An algorithm for glycemic control. Endocr Pract. 2009; 15(6): 540–559
   PubMed Web of Science ®Google Scholar
• . Knudsen LB, Nielsen PF, Huusfeldt PO, . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000; 43(9):1664–1669
   PubMed Web of Science ®Google Scholar
• . Farilla L, Hui H, Bertolotto C, . Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002; 143(11):4397–4408
   PubMed Web of Science ®Google Scholar
• . Buteau J, Foisy S, Joly E, Prentki M. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003; 52(1):124–132
   PubMed Web of Science ®Google Scholar
• . Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696–1705
   PubMed Web of Science ®Google Scholar
• . Victoza [package insert]. Novo Nordisk A/S, Bagsvaerd, Denmark; May 2011. http://www.novo-pi.com/victoza.pdf. Accessed June 24, 2011
   Google Scholar
• . Garber A, Henry R, Ratner R, . Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): Randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373(9662):473–481
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Frid A, Hermansen K, . efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Marre M, Shaw J, Brandle M, . Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26(3):268–278
   PubMed Web of Science ®Google Scholar
• . Zinman B, Gerich J, Buse J, . efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. 2009; 32(7):1224–1230
   PubMed Web of Science ®Google Scholar
• . Russell-Jones D, Vaag A, Schmitz O, ; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: A randomised controlled trial (LEAD-5 met+SU). Diabetologia. 2009; 52(10):2046–2055
   PubMed Web of Science ®Google Scholar
• . Buse J, Rosenstock J, Sesti G, ; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374(9683):39–47
   PubMed Web of Science ®Google Scholar
• . Pratley RE, Nauck M, Bailey T, ; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375(9724):1447–1456
   PubMed Web of Science ®Google Scholar
• . Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13(4):348–356
   PubMed Web of Science ®Google Scholar
• . Buse JB, Sesti G, Schmidt WE, ; Liraglutide Effect Action in Diabetes-6 Study Group. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33(6): 1300–1303
   PubMed Web of Science ®Google Scholar
• . Pratley R, Nauck M, Bailey T, ; 1860-LIRA-DPP-4 Study Group. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: A randomised, parallel-group, open-label trial. Int J Clin Pract. 2011; 65(4):397–407
   PubMed Web of Science ®Google Scholar
• . Pratley R, Nauck M, Bailey T, ; 1860-LIRA-DPP-4 Study Group. Switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide further improves glycemic control and weight loss in patients with type 2 diabetes. Diabetes. 2011; 60( suppl 1): A307–A308
   Web of Science ®Google Scholar
• . Rosenstock J, DeVries JH, Seufert J, . A new type 2 diabetes treatment paradigm: Sequential addition of liraglutide to metformin and then basal insulin detemir. Diabetes. 2011; 60( suppl 1):A76
   Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA, ; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care. 2008; 31(1):102–104
   PubMed Web of Science ®Google Scholar
• . Jendle J, Nauck MA, Matthews DR, ; LEAD-2 and LEAD-3 Study Groups. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009; 11(12):1163–1172
   PubMed Web of Science ®Google Scholar
• . Bode BW, Testa MA, Magwire M, ; LEAD-3 Study Group. Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: Results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12(7):604–612
   PubMed Web of Science ®Google Scholar
• . Hermansen K, Kolotkin RL, Hammer M, Zdravkovic M, Matthews D. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. Prim Care Diabetes. 2010; 4(12):113–117
   PubMedGoogle Scholar
• . Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med. 2011; 28(3):333–337
   PubMed Web of Science ®Google Scholar
• . Montanya E, Pratley R, Nauck M, . Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes. Diabetes. 2011; 60( suppl 1):A307
   Web of Science ®Google Scholar
• . Schmidt WE, Christiansen JS, Hammer M, Zychma MJ, Buse JB. Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: Results from a randomized, open-label study. Diabet Med. 2011; 28(6):715–723
   PubMed Web of Science ®Google Scholar
• . Patel A; , ADVANCE Collaborative GroupMacMahon S, . Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007; 370(9590):829–840
   PubMed Web of Science ®Google Scholar
• . Hansson L, Zanchetti A, Carruthers SG, . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755–1762
   PubMed Web of Science ®Google Scholar
• . Grieve DJ, Cassidy RSGreen BD. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: Potential therapeutic benefits beyond glycaemic control? Br J Pharmacol. 2009; 157(8):1340–1351
   PubMed Web of Science ®Google Scholar
• . Fonseca V, Madsbad S, Falahati A, Zychma M, Plutzky J. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: A meta-analysis of six clinical trials (LEAD). Diabetes. 2009; 58( suppl 1):A146
   PubMedGoogle Scholar
• . Buse JB, Garber A, Rosenstock J, . Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. J Clin Endocrinol Metab. 2011; 96(6):1695–1702
   PubMed Web of Science ®Google Scholar
• . Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: An overview of the LEAD 1–5 studies. Diabetes Obes Metab. 2009; 11( suppl 3):26–34
   PubMed Web of Science ®Google Scholar
• . Horowitz M, Vilsbøll T, Zdravkovic M, Hammer M, Madsbad S. Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Diabetes Obes Metab. 2008; 10(7):593–596
   PubMed Web of Science ®Google Scholar
• . Nauck MA, El-Ouaghlidi A, Hompesch M, . No impairment of hypoglycemic counterregulation via glucagon with NN2211 (liraglutide), a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes. 2003; 52( suppl 1):A128
   Google Scholar
• . Buse JB, Henry RR, Han J, ; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11):2628–2635
   PubMed Web of Science ®Google Scholar
• . Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26( suppl 3):S18–S24
   PubMed Web of Science ®Google Scholar
• . Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009; 32(5):834–838
   PubMed Web of Science ®Google Scholar
• . Januvia [package insert]. Merck and Co., Inc., Whitehouse Station, NJ; April 2011. http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed June 24, 2011
   Google Scholar
• . Byetta [package insert] Amylin Pharmaceuticals, Inc., San Diego, CA; September 2010. http://pi.lilly.com/us/byetta-pi.pdf. Accessed June 24, 2011
   Google Scholar
• . Knudsen LB, Madsen LW, Andersen S, . Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010; 151(4):1473–1486
   PubMed Web of Science ®Google Scholar
• . Garber JR. AACE Statement on Liraglutide (March 2010). https://www.aace.com/publications/online-news/March-16-2010. Accessed June 24, 2011
   Google Scholar
• . Irie S, Matsumura Y, Zdravkovic M, Jacobsen LV, Kageyama S. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: A randomized, double-blind, placebo-controlled dose-escalation study. Int J Clin Pharmacol Ther. 2008; 46(6):273–279
   PubMed Web of Science ®Google Scholar
• . Bjornsdottir I, Olsen A, Larsen U, . Metabolism and excretion of the once-daily human GLP-1 analogue liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Diabetologia. 2008; 51( suppl 1):S356
   Web of Science ®Google Scholar
• . Flint A, Nazzal K, Jagielski P, . Influence of hepatic impairment on pharmacokinetics of the long-acting human GLP-1 analogue liraglutide. Diabetes. 2007; 56( suppl 1):A145
   Web of Science ®Google Scholar
• . Jacobsen LV, Hindsberger C, Robson R, . Pharmacokinetics of the long-acting human GLP-1 analogue liraglutide in subjects with renal impairment. Diabetes. 2007; 56( suppl 1):A137
   PubMed Web of Science ®Google Scholar
• . Malm-Erjefält M, Ekblom M, Brønsted L, . A randomised, double-blind, cross-over trial investigating the effect of liraglutide on the absorption pharmacokinetics of concomitantly administered oral drugs in healthy subjects. Diabetes. 2008;( suppl 1):P434
   Google Scholar
• . Jacobsen LV, Brønsted L, Vouis L, . A randomized, double-blind, cross-over trial investigating the effect of liraglutide on the absorption of an oral contraceptive drug. Diabetes. 2008; 57( suppl 1):P2047
   Web of Science ®Google Scholar
• . Degn KB, Juhl CB, Sturis J, . One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53(5):1187–1194
   PubMed Web of Science ®Google Scholar
• . Elbrønd B, Jakobsen G, Larsen S, . Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002; 25(8):1398–1404
   PubMed Web of Science ®Google Scholar